CCO Infectious Disease Podcast

Integrating New Data on HIV Adverse Events From IAS 2023: Pharmacist Perspectives

Episode Summary

Listen as pharmacist experts Brooke Bates, PharmD, BCPS, AAHIVP, and Neha Sheth Pandit, PharmD, AAHIVP, BCPS, discuss the most clinically relevant studies on HIV adverse events presented at IAS 2023, with a special focus on cardiovascular risk and weight considerations with ART.

Episode Notes

In this episode, Brooke Bates, PharmD, BCPS, AAHIVP, and Neha Sheth Pandit, PharmD, AAHIVP, BCPS, discuss the most clinically relevant studies on HIV adverse events presented at IAS 2023, including: 

• REPRIEVE study of pitavastatin for cardiovascular prevention in people living with HIV at low to moderate cardiovascular risk
• Data on weight change with switch from integrase inhibitor–based ART to doravirine/islatravir in the P017 and P018 studies
• DEFINE study evaluating weight change after a switch to DRV/COBI/FTC/TAF in people living with HIV who experienced weight gain with integrase inhibitor–based ART

Faculty: 

Brooke Bates, PharmD, BCPS, AAHIVP
Specialty Pharmacy Clinical Manager 
Pediatric HIV Clinical Pharmacist
Indiana University Health
Indianapolis, Indiana

Neha Sheth Pandit, PharmD, AAHIVP, BCPS
Professor
Vice Chair for Research and Scholarship
Department of Practice, Sciences, and Health Outcomes Research
School of Pharmacy
University of Maryland 
Clinical Pharmacist
THRIVE Program
Baltimore, Maryland

Link to full program: 
https://bit.ly/3ZjSFhg